Furthermore, STAD patients with MTF1 genetic alteration illustrated a good prognosis in DSS (p = 0.0325) and OS (p = 0.0461), but not DFS (p = 0.334) and PFS (p = 0.0608) (Fig. 5D). This evidence concerns the gene MTF1 and gastric adenocarcinoma.